Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use

Claim 1

A polypeptide of formula (I) ##STR39## wherein A is C 1-12 alkyl, C 7-10 phenylalkyl or a group of formula RCO--, whereby (i) R is hydrogen, C 1-11 alkyl, phenyl or C 7-10 phenylalkyl, or (ii) RCO-- is (a) an L- or D-phenylalanine residue optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy (b) --Asn-- or the residue of a natural α-amino acid having a hydrocarbyl side chain other than defined under (a) above or of a corresponding D-amino acid, or (c) a dipeptide residue in which the individual amino acid residues are the same or different and are selected from those defined under (a) and/or (b) above, the α-amino group of amino acid residues (a) and (b) and the N-terminal amino group of dipeptide residues (c) being optionally mono- or di-C 1-12 alkylated, A' is hydrogen or, when A is C 1-12 alkyl or C 7-10 phenylalkyl, also C 1-12 alkyl or C 7-10 phenylalkyl, B is --Phe-- optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, C is --(L)-- or --(D)--Trp-- optionally α-N-methylated and optionally benzene-ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, D is --Lys-- optionally α-N-methylated and optionally ε-N-C 1-3 alkylated, E is --Thr-- or --Ala-- each in (D)- or (L)- form and each being optionally α-N-methylated, F is a group of formula ##STR40## wherein R 1 is hydrogen or C 1-3 alkyl, R 2 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester, R 3 is hydrogen, C 1-3 alkyl, phenyl, benzyl or C 9-10 phenylalkyl, R 4 is hydrogen, C 1-3 alkyl or, when R 3 is hydrogen or methyl, also a group of formula --CH(R 5 )--X wherein R 5 is hydrogen, --(CH 2 ) 2 --OH, --(CH 2 ) 3 --OH, --CH 2 --OH, --CH(CH 3 )--OH, isobutyl or benzyl and X is a group of formula ##STR41## wherein R 1 and R 2 have the meanings given above, R 6 is hydrogen or C 1-3 alkyl and R 7 is hydrogen, C 1-3 alkyl, phenyl or C 7-10 phenylalkyl, the group --CH(R 5 )--X having the D- or L-configuration, and Y 1 and Y 2 are each hydrogen or together represent a direct bond, whereby the residues in the 1- and 6-position each independently have the L- or D-configuration, with the proviso (i) that D- and/or L-cysteine residues are present at the 1- and 6-positions only, and (ii) that when R 5 is benzyl, X is a group of formula ##STR42## or a group of formula --COOR 1 , wherein R 1 is C 1-3 alkyl, or a pharmaceutically acceptable acid addition salt or complex thereof.